Fangsheng Pharmaceutical: Subsidiary Xiangqin Fever-reducing Granules Approved for Clinical Trials for New Drug

Fangsheng Pharmaceuticals announced that its wholly-owned subsidiary, Yunnan Fangsheng Ronghe Pharmaceutical Co., Ltd., together with Yunnan University of Traditional Chinese Medicine, have received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration for the innovative traditional Chinese medicine Xiangqin Jiere Keli Granules jointly developed by them. The medicine is classified as Category 1.1 traditional Chinese medicine and is used for adults with symptoms of damp-heat in exterior syndrome of influenza. As of June 30, 2025, the accumulated research and development investment for this medicine project is approximately 1605.69 million yuan. Xiangqin Jiere Keli Granules as an innovative traditional Chinese medicine, has not yet been launched in domestic or foreign markets. Traditional Chinese medicines are widely used in respiratory system diseases, and in recent years, the sales of traditional Chinese medicines for respiratory system diseases in China's three major terminal markets have all exceeded 80 billion yuan.